Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Other Investing Activities

Investing cash flows not reported separately.

Haemonetics CorporationNYSE: HAE

Other Investing Activities · Q1 FY2027 · quarter ended Jun 2026

Other investing activities dips below year-ago levels

Q1 FY2027 other investing activities of $5.33M (cash outflow) fell 53.5% year over year, behind the +193.1% change in trailing-twelve-month other investing activities. Sequentially, it fell 42.7% from the prior quarter.

Context

  • Other investing activities amounted to 6.6% of revenue in FY2026, up 5.5 pp from a year earlier.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -53.5% toward the trailing-twelve-month pace of +193.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$5.33M-42.7% QoQ
Last fiscal yearMar 2026
-$87.96M+486.3% YoY
LTMJun 2026
-$80.98M+193.1% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.5%——
1 year+486.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2026
(87.96M) USD
Year-over-year change
-486.3%

Other Investing Activities vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 other investing activities of $80.98M is the 4th largest of the 10 companies compared; the peer median is $4M.
  • Its year-over-year change of +193.1% is the 2nd highest of 8, against a peer median of -27.6%.
  • Other investing activities amounts to 6.0% of revenue for HAE, versus a peer median of 0.3%.
HAE Competitors Peer median
Other Investing Activities for HAE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$328.97M -44316.7%—14.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026$255.6M ——163.8%
ITGRInteger Holdings CorporationLTM Jul 2026$191.12M -493.5%—10.4%
HAEHaemonetics CorporationLTM Jun 2026$80.98M +193.1%—6.0%
QDELQuidelOrtho CorporationLTM Mar 2026$48.5M -27.6%—1.8%
BHCBausch Health Companies Inc.LTM Jun 2026$32.01M +1513.4%+63.0%0.3%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$4M -20.0%-20.6%0.1%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
WRBYWarby Parker Inc.LTM Jun 2026$0 +100.0%—0.0%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding HAE) $4M-27.6%+21.2%0.3%

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income43.38M115.4M117.56M167.68M97.31M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
Deferred Income Tax5.01M4.78M(1.01M)(15.7M)(714K)
Stock-Based Compensation24.36M25.58M28.33M29.64M33.83M
Change in Working Capital(15.18M)25.5M(63.07M)(91.98M)(23.65M)
Accounts Receivables(34.97M)(24.42M)(24.19M)6.96M(14.88M)
Inventory24.31M30.75M(60.06M)(64.7M)47.36M
Accounts Payables039.82M00(16.57M)
Other Working Capital(4.51M)(20.65M)21.19M(34.24M)(39.56M)
Other Non-Cash Items16.95M8.48M2.73M(23.49M)74.74M
Operating Cash Flow172.26M273.06M181.75M181.73M293.22M
Capital Expenditures(96.51M)(110.19M)(38.13M)(39.28M)(32.78M)
Acquisitions (Net)8.14M(2M)(242.35M)(107.62M)1.38M
Purchases of Investments0(33.21M)000
Sales of Investments00000
Other Investing Activities2.02M1.61M(41.91M)(15M)(87.96M)
Investing Cash Flow(86.35M)(143.79M)(322.39M)(161.9M)(179.55M)
Debt Repayment(17.5M)(9.63M)37.75M447.31M(6.25M)
Common Stock Issued6.55M01.33M(1.91M)7.89M
Common Stock Repurchased0(75M)0(225M)(175M)
Dividends Paid00000
Other Financing Activities(4.8M)(15.74M)(922K)(111.58M)(5.1M)
Financing Cash Flow(15.75M)(100.36M)38.16M108.82M(178.46M)
Effect of Forex Changes(2.98M)(3.94M)(3.19M)(685K)3.46M
Net Change in Cash67.19M24.97M(105.67M)127.96M(61.32M)
Free Cash Flow75.75M162.87M143.63M142.45M260.44M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.